Patents Represented by Attorney, Agent or Law Firm John F. Levis
-
Patent number: 7776863Abstract: The invention encompasses pharmaceutical compositions and methods for using Compound 1 in combination with other agents for treating patients with AIDS or HIV infection.Type: GrantFiled: February 24, 2005Date of Patent: August 17, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Pin-Fang Lin, Beata Nowicka-Sans, Gregory Yamanaka
-
Patent number: 7772221Abstract: There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: January 25, 2008Date of Patent: August 10, 2010Assignee: Bristol-Meyers Squibb CompanyInventors: Lawrence R. Marcin, Andrew C. Good, Yong-Jin Wu, Dmitry S. Zuev, Richard E. Olson, Nenghui Wang
-
Patent number: 7745463Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.Type: GrantFiled: June 15, 2009Date of Patent: June 29, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Tao Wang, Ying Han, John F. Kadow, Zhongxing Zhang, Nicholas A. Meanwell
-
Patent number: 7745470Abstract: There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: March 8, 2006Date of Patent: June 29, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Lorin A. Thompson, III, Kenneth M. Boy, Jianliang Shi, John E. Macor
-
Patent number: 7745625Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.Type: GrantFiled: February 25, 2005Date of Patent: June 29, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Yasutsugu Ueda, Timothy P. Connolly, John F. Kadow, Nicholas A. Meanwell, Tao Wang, Chung-Pin H. Chen, Kap-Sun Yeung, Zhongxing Zhang, David Kenneth Leahy, Shawn K. Pack, Nachimuthu Soundararajan, Pierre Sirard, Kathia Levesque, Dominique Thoraval
-
Patent number: 7732434Abstract: There is provided a series of heterocyclic-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: April 8, 2008Date of Patent: June 8, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Shuhao Shi, Samuel Gerritz, Shirong Zhu
-
Patent number: 7723338Abstract: The instant disclosure provides crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, salts and solvates thereof. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s).Type: GrantFiled: January 26, 2006Date of Patent: May 25, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Chung-Pin H. Chen, Qi Gao, David K. Leahy, Srividya Ramakrishnan, Venkatramana M. Rao, Anne I. Song
-
Patent number: 7714019Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with amido piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.Type: GrantFiled: April 2, 2009Date of Patent: May 11, 2010Assignee: Bristol-Myers Squibb CompanyInventors: John F. Kadow, Qiufen May Xue, Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell
-
Patent number: 7678784Abstract: There is provided a series of oxime-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: November 15, 2007Date of Patent: March 16, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Yong-Jin Wu, Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Patent number: 7662823Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.Type: GrantFiled: January 15, 2009Date of Patent: February 16, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro-Ren, John D. Matiskella, Yasutsugu Ueda
-
Patent number: 7612069Abstract: There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: June 20, 2006Date of Patent: November 3, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Samuel Gerritz, Weixu Zhai, Shuhao Shi, Shirong Zhu, Andrew C. Good, Lorin A. Thompson, III
-
Patent number: 7601751Abstract: There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and R8 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: August 23, 2006Date of Patent: October 13, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Lorin A. Thompson, III, Jianliang Shi, F. Christopher Zusi, Michael F. Dee, John E. Macor
-
Patent number: 7598380Abstract: A method of preparing azaindole compounds for antiviral use having the formulaType: GrantFiled: July 25, 2006Date of Patent: October 6, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Wansheng Liu, Sunil S. Patel, Nicolas Cuniere, Yvonne Lear, Prashant P. Deshpande, Jeffrey N. Simon, Chiajen Lai, Annie J. Pullockaran, Nachimuthu Soundararajan, Jeffrey T. Bien
-
Patent number: 7582468Abstract: The present invention relates to a process for preparing (2R,3S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butane comprising contacting a mutagenized Rhodococcus erythropolis having ATCC deposit no. PTA-6648 with (3S)-1-halo-2-oxo-3-(protected)amino-4-substituted butane substrate. The present invention also relates to a process comprising mixing (2R,3S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butane with at least one base in the presence of at least one solvent to produce a reaction mixture containing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane. The present invention further relates to a process comprising crystallizing the (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane out of the reaction mixture by concurrently adding water and the reaction mixture together. The present invention is also directed to a mutagenized Rhodococcus erythropolis having ATCC deposit no. PTA-6648.Type: GrantFiled: March 1, 2006Date of Patent: September 1, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Nigel Ian Bowers, Paul M. Skonezny, Gregory L. Stein, Thomas Franceschini, Shu-Jen Chiang, Wendy L. Anderson, Li You, Zizhuo Xing
-
Patent number: 7572810Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.Type: GrantFiled: May 16, 2007Date of Patent: August 11, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Tao Wang, Ying Han, John F. Kadow, Zhongxing Zhang, Nicholas A. Meanwell
-
Patent number: 7557137Abstract: There is provided a series of novel substituted gamma-lactams of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present invention is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: August 4, 2003Date of Patent: July 7, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Carl P. Decicco, Andrew J. Tebben, Lorin A. Thompson, III, Andrew P. Combs
-
Patent number: 7550445Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.Type: GrantFiled: June 14, 2006Date of Patent: June 23, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Manoj Nerurkar, Vijay Naringrekar
-
Patent number: 7531552Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with amido piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.Type: GrantFiled: December 20, 2007Date of Patent: May 12, 2009Assignee: Bristol-Myers Squibb CompanyInventors: John F. Kadow, Qiufen May Xue, Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell
-
Patent number: 7504399Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with indole and azaindole piperazine enamine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to a compound of Formula I useful for the treatment of HIV and AIDS.Type: GrantFiled: May 15, 2007Date of Patent: March 17, 2009Assignee: Bristol-Meyers Squibb CompanyInventors: Tao Wang, John F. Kadow, Zhongxing Zhang, Zhiwei Yin, Nicholas A. Meanwell
-
Patent number: 7501419Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with 4-squarylpiperazine derivatives that possess unique antiviral activity.Type: GrantFiled: April 19, 2007Date of Patent: March 10, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Daniel H. Deon, Edward H. Ruediger